Comparative Pharmacology
Head-to-head clinical analysis: GIAZO versus HYDROCORTISONE AND ACETIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GIAZO versus HYDROCORTISONE AND ACETIC ACID.
GIAZO vs HYDROCORTISONE AND ACETIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Balsalazide is a prodrug that is converted by colonic bacteria into mesalamine (5-aminosalicylic acid), which inhibits prostaglandin and leukotriene production, reducing colonic inflammation.
Hydrocortisone is a corticosteroid that binds to the glucocorticoid receptor, leading to increased lipocortin synthesis, inhibition of phospholipase A2, decreased arachidonic acid release, and reduced prostaglandin and leukotriene production; it also suppresses cytokine expression and immune cell migration. Acetic acid is a weak acid that lowers local pH, inhibiting bacterial and fungal growth and disrupting microbial cell membranes.
Adults: 2 tablets (1.2 g) orally three times daily (3.6 g/day) for up to 6 weeks.
Instill 5 drops into affected ear(s) twice daily for 7-10 days; or as directed by physician.
None Documented
None Documented
Terminal elimination half-life approximately 0.5-1.0 hour for 5-ASA (active); metabolite half-life ~5-10 hours. Clinical context: short half-life necessitates multi-matrix release formulation for once-daily dosing in ulcerative colitis.
Plasma t1/2: 1.5-2 hours; biological t1/2: 8-12 hours (based on HPA axis suppression).
Primarily metabolized in the gut mucosa and liver to N-acetyl-5-aminosalicylic acid. Renal excretion of acetylated metabolite accounts for ~25-30% of dose; fecal excretion of parent drug and metabolite ~50-60%. Biliary excretion minimal.
Renal: ~60-70% as metabolites; biliary/fecal: ~10-15%; unchanged drug: <5%.
Category C
Category D/X
Corticosteroid
Corticosteroid